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Abstract
TRPM7 is a ubiquitous divalent-selective ion channel with its own kinase domain. Recent studies have shown that
suppression of TRPM7 protein expression by RNA interference increases resistance to ischemia-induced neuronal cell death
in vivo and in vitro, making the channel a potentially attractive pharmacological target for molecular intervention. Here, we
report the identification of the 5-lipoxygenase inhibitors, NDGA, AA861, and MK886, as potent blockers of the TRPM7
channel. Using a cell-based assay, application of these compounds prevented cell rounding caused by overexpression of
TRPM7 in HEK-293 cells, whereas inhibitors of 12-lipoxygenase and 15-lipoxygenase did not prevent the change in cell
morphology. Application of the 5-lipoxygenase inhibitors blocked heterologously expressed TRPM7 whole-cell currents
without affecting the protein’s expression level or its cell surface concentration. All three inhibitors were also effective in
blocking the native TRPM7 current in HEK-293 cells. However, two other 5-lipoxygenase specific inhibitors, 5,6-dehydro-
arachidonic acid and zileuton, were ineffective in suppressing TRPM7 channel activity. Targeted knockdown of 5-
lipoxygenase did not reduce TRPM7 whole-cell currents. In addition, application of 5-hydroperoxyeicosatetraenoic acid
(5-HPETE), the product of 5-lipoxygenase, or 5-HPETE’s downstream metabolites, leukotriene B4 and leukotriene D4, did not
stimulate TRPM7 channel activity. These data suggested that NDGA, AA861, and MK886 reduced the TRPM7 channel activity
independent of their effect on 5-lipoxygenase activity. Application of AA861 and NDGA reduced cell death for cells
overexpressing TRPM7 cultured in low extracellular divalent cations. Moreover, treatment of HEK-293 cells with AA861
increased cell resistance to apoptotic stimuli to a level similar to that obtained for cells in which TRPM7 was knocked down
by RNA interference. In conclusion, NDGA, AA861, and MK886 are potent blockers of the TRPM7 channel capable of
attenuating TRPM7’s function during cell stress, making them effective tools for the biophysical characterization and
suppression of TRPM7 channel conductance in vivo.
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Introduction
TRPM7, a member of the transient receptor potential
melastatin-like (TRPM) ion channel subfamily, is a widely
expressed bifunctional protein with both ion channel and a-kinase
domains [1,2]. Several physiological functions have been ascribed
to the channel-kinase including magnesium and rare metal
homeostasis, melanopore maturation, kidney stone formation,
sensing of sheer stress, synaptic vesicle fusion, thymopoiesis, and
cell adhesion [3,4,5,6,7,8,9,10]. In addition, the channel also
contributes to ischemic brain pathology. It has been shown that
TRPM7 channel activity is up-regulated in oxygen glucose
deprived cortical neurons and that knockdown of TRPM7
expression by RNA interference in cultured neurons and the
hippocampus delayed anoxic cell death [11,12].
Several modulators of TRPM7 channel activity, including PIP2,
Mg
2+,M g
2+NATP, polyvalent cations, and H
+ have been identified
[1,13,14,15,16]. The phospholipid PIP2 gates the channel such
that activation of receptors coupled to phospholipase C (PLC)
inhibits channel activity by depleting cellular PIP2 [15,17]. Mg
2+,
Mg
2+NATP, H
+, and polyvalent cations are believed to inhibit
channel activity by screening PIP2 head group charges [13]. Thus,
the prevailing view is that in unstimulated cells a large fraction of
TRPM7’s channel activity is suppressed by Mg
2+,M g
2+NATP, and
other factors, and that activation of the channel is achieved by
reversing the action of these modulators on the channel [18].
To better understand the mechanism(s) by which the channel
contributes to the demise of cells under cellular stress, we
characterized the cellular effects produced by increased TRPM7
channel activity employing HEK-293 cells as a model [10].
Overexpression of the channel-kinase in HEK-293 cells produced
cell rounding that was dependent upon the calcium-dependent
protease m-calpain [10]. More recently, we have shown that
TRPM7 activates m-calpain through reactive oxygen species
(ROS) dependent activation of the stress-activated protein kinases
p38 MAP kinase and c-Jun N-terminal kinase (JNK) in HEK-293
cells [19]. During the course of our investigation into the
mechanism by which overexpression of TRPM7 caused loss of
cell adhesion, we discovered that application of the non-specific
lipoxygenase inhibitor NDGA attenuated cell rounding and loss of
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11161adhesion produced by influx of divalent cations through the
channel. Electrophysiological measurements demonstrated that
application of NDGA potently inhibited TRPM7 channel activity,
suggesting that a lipoxygenase (LOX) may be involved in
regulating the channel. Lipoxygenases are a family of calcium-
dependent dioxygenases, including 5-lipoxygenase (5-LOX), 12-
lipoxygenase (12-LOX), and 15-lipoxygenase (15-LOX), that
metabolize arachidonic acid to distinct biologically active fatty
acid hydroperoxides, such as leukotrienes and hydroyeicosater-
aenoic acids [20]. These metabolites take part in numerous cell
processes, including inflammation, proliferation, cell invasion,
angiogenesis, cell adhesion, and cell spreading [21,22,23,24]. It is
well known that lipid molecules modulate several members of the
TRP family [25]. In particular, products of lipoxygenase have
been demonstrated to directly modulate TRPV1 channel activity
[26]. Activation of histamine and bradykinin receptors stimulates
TRPV1 channel activity in a 12-LOX-dependent manner [27,28].
Thus, our discovery that NDGA blocked TRPM7 channel activity
initially suggested to us that TRPM7 channel activity may be
similarly controlled by a lipoxygenase. However, results from our
experiments indicate that these compounds block TRPM7
channel activity independent of their actions on 5-LOX. Here
we identify the 5-LOX inhibitors NDGA, AA861, and MK886 as
potent blockers of the TRPM7 channel and demonstrate that
depletion of TRPM7 channel activity by RNA interference or by
treatment of cells with TRPM7 channel blockers reduces cell
death caused by apoptotic stimuli.
Results
Previously, we have shown that overexpression of TRPM7 in
HEK-293 cells caused cell rounding and loss of adhesion that
occurred in a channel-dependent and kinase-independent
manner [10]. Cell rounding induced by TRPM7 could be
prevented by pharmacological inhibition of calpain as well as by
reduction of m-calpain protein levels by RNA interference. An
investigation into the mechanism by which TRPM7 controls m-
calpain revealed that application of NDGA, an inhibitor that is
effective against 5-, 12- and 15-LOX, inhibited TRPM7-
dependent cell rounding with a measured IC50 (half maximal
inhibitory concentration) of 6.3 mM (Fig. 1A,B) [29,30]. To
further investigate a potential role for a lipoxygenase in
controlling TRPM7 channel function, we employed a cell
rounding assay with the 293-TRPM7 cell line, which overex-
presses TRPM7 in HEK-293 cells in a tetracycline-inducible
manner [10]. Inhibitors of 12-LOX (baicalein) and 15-LOX
(PD146176) were ineffective in blocking TRPM7-dependent cell
rounding (Fig. 1A,B). In addition, indomethacin, an inhibitor of
cyclooxygenases (an enzyme that also uses arachidonic acid as a
substrate), did not block cell rounding. However, the 5-LOX
inhibitors AA861 and MK886, which binds to and inhibits 5-
lipoxygenase-activating-protein (FLAP), suppressed TRPM7-in-
duced cell rounding with measured IC50so f6 . 0a n d8 . 6mM,
respectively (Fig. 1A,B) [21]. The oral 5-LOX inhibitor zileuton,
however, was not effective in blocking cell rounding (Fig. 1A, B).
To assess the ability of the 5-LOX inhibitors to block TRPM7
channel activity, we next performed whole-cell recordings of
TRPM7 current from cells overexpressing the channel-kinase
(Fig. 2A-F). NDGA and AA861 completely blocked TRPM7
channel activity at the concentrations used to inhibit cell rounding
(Fig. 2A,B,E,F), with higher concentrations of the compounds
blocking more rapidly (Fig. S1). We were unable to measure the
effect of MK886 on channel conductance at lower concentrations
due to the compound’s slow onset of inhibition and tendency to
destroy the seal and increase leak current. However, higher
concentrations of the compound were very effective in blocking
TRPM7 channel activity (Fig. 2C,D). Consistent with zileuton’s
lack of effect on TRPM7-induced cell rounding, the 5-LOX
inhibitor had no effect on whole-cell currents (Fig. 2 G,H), leaving
it unclear whether 5-LOX was playing an important role in
controlling TRPM7 currents.
To investigate whether 5-LOX was involved in the regulation of
TRPM7 channel activity, two Dicer substrate small interfering RNAs
(dsiRNAs) targeting human 5-lipoxygenase (dsiLOX5-1 and dsi-
LOX5-2) were designed and characterized for their ability to
modulate 5-LOX expression. Transfection of dsiLOX5-1 and
dsiLOX5-2 suppressed expression of heterologously expressed
GFP-5-LOX by 53% and 67%, respectively, without affecting
expression of heterologously expressed GFP-15-LOX-2 (Fig. S2A,B).
Transfection of dsiLOX5-1 and dsiLOX5-2 into 293-TRPM7 cells
each decreased expression of the endogenous 5-lipoxygenase by
greater than 50% compared to cells transfected with the non-
silencing control dsiRNA (dsiCT) (Fig. 3A). Knockdown of
endogenous 5-LOX partially suppressed TRPM7-induced cell
rounding (Fig. 3B,C), however, no appreciable differences in whole-
cell currents from 293-TRPM7 cells transfected with dsiLOX5-2
compared to cells transfected with the non-silencing control dsiCT
were observed (Fig. 3D). This data indicated that knockdown of 5-
LOXlikelyattenuatedcellroundingbylimitingROSproductionand
calpain activation, rather than by directly interfering with TRPM7
channel activity [19].
To further determine whether the 5-LOX pathway was
involved in the regulation of the TRPM7 channel, we tested
whether application of 5-hydroperoxyeicosatetraenoic acid (5-
HPETE), the product of 5-LOX, could reactivate TRPM7 whole-
cell currents in the presence of AA861. However, neither
application of 5-HPETE or its downstream metabolites, leukotri-
ene B4 (LTB4) and leukotriene D4 (LTD4), perfused into the
extracellular buffer or added to the internal pipette solution, were
able to restore channel activity (Fig. S3). We also investigated the
possibility that build-up of arachidonic acid from 5-LOX
inhibition was responsible for blocking TRPM7 channel activity.
However, application of 10 mM arachidonic acid did not affect
whole-cell currents (Fig. S4C,D). Moreover, another 5-LOX
specific inhibitor, zileuton, an oral drug for asthma, did not block
TRPM7 channel activity within the time-course of our electro-
physiological recordings (Fig. 2G,H) [21]. Similar results were
obtained for the 5-LOX inhibitor 5,6-dehydro-arachidonic acid
(5,6-DAA) (Fig. S4A,B). Another possibility we considered was that
5-LOX could be directly interacting with TRPM7. However, co-
immunoprecipitation experiments using cell lysates from cells
heterologously expressing TRPM7 and the GFP fusion protein of
5-lipoxygenase (GFP-5-LOX) failed to reveal an interaction
between theses two proteins (data not shown). Collectively, these
results indicated that NDGA, AA861, and MK886 were blocking
TRPM7 channel activity independent of their actions on 5-LOX.
Since the results thus far indicated that NDGA, AA861, and
MK886 were not blocking TRPM7 channel activity by interfering
with 5-LOX, we next investigated whether these compounds
blocked TRPM7 channel activity by interfering with TRPM7
protein expression or with trafficking of the ion channel to the cell
surface. However, the expression levels of TRPM7 in 293-TRPM7
cells treated with these 5-LOX inhibitors were unchanged
(Fig. 4A). In addition, we were unable to detect any significant
difference in cell surface biotinylation of TRPM7 in cells treated
with the 5-LOX inhibitors (Fig. 4A) or in cells in which 5-LOX
has been knocked down (Fig. 4B). These results indicated that the
5-LOX inhibitors were not blocking TRPM7 channel activity by
TRPM7 Channel Blockers
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cell surface.
TRPM7 is a ubiquitously expressed and constitutively active
divalent cation channel whose basal activity is regulated by
intracellular levels of Mg
2+ and Mg
2+NATP [1,18]. An endogenous
TRPM7-like Mg
2+-nucleotide-regulated metal current (MagNuM)
and magnesium-inhibited cation (MIC) channel have been
described in multiple cell types including RBL-2H3 cells, human
retinoblastoma cells, cardiomycytes, glia, as well as neurons
[1,31,32,33,34,35]. The TRPM7-like current is also present in
HEK-293 cells and we have recently shown that this current is
constituted by TRPM7 [10]. All three compounds, NDGA,
AA861, and MK886, blocked the endogenous TRPM7-like
current in HEK-293 cells (Fig. 5), indicating that these compounds
are effective reagents for inhibiting the native TRPM7 channel.
Knockdown of TRPM7 in isolated cortical neurons or in the
hippocampus delayed neuronal death caused by oxygen glucose
deprivation and brain ischemia, respectively [11,36]. In a recent
study, TRPM7 was additionally shown to increase cell death of
neurons and HEK-293 cells cultured in low concentrations
of extracellular divalent cations [36]. Interestingly, application of
AA861 and NDGA reduced cell death of cells overexpressing
TRPM7 that were cultured in low extracellular divalent cations
(0 mM Mg
2+/0.5 mM Ca
2+) (Fig. 6A). Zileuton, which does not
block the TRPM7 channel (Fig. 2G,H), did not reduce cell death
under these conditions. MK886 was not employed in this assay,
because it increased cell toxicity under these experimental
conditions. While knockdown of TRPM7 in neurons is protective
against oxygen glucose deprivation, it is unknown whether
reducing TRPM7 expression in other cell types defends against
Figure 1. Inhibitors of 5-LOX block TRPM7-mediated cell rounding. (A) Application of the 5-LOX inhibitors NDGA (10 mM), AA861 (10 mM),
and MK886 (10 mM) to 293-TRPM7 expressing cells reduced cell rounding. In contrast, treatment of 293-TRPM7 cells with the cyclooxygenase inhibitor
indomethacin (10 mM), 12-LOX inhibitor baicalein (5 mM), 15-LOX inhibitor PD146176 (2 mM), and the 5-LOX inhibitor zileuton (50 mM) did not block
TRPM7-induced cell rounding. (B) Quantification of the degree of cell rounding under the conditions depicted in (A). Values are mean 6 standard
deviation of at least three independent experiments. A x
2 test was employed to assess differences in cell rounding between 293-TRPM7 cells treated
with the different inhibitors. An asterisk indicates treatments that produced a decrease in cell rounding that was significantly different from 293-
TRPM7 cells grown in tetracycline.
doi:10.1371/journal.pone.0011161.g001
TRPM7 Channel Blockers
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M7shRNA2 cell line expressing a shRNA targeting human
TRPM7 under tetracycline (TET) control, in addition to the
293-shRNA-C cell line expressing a non-silencing control shRNA
[10]. Western blotting and electrophysiological measurements
demonstrated that expression of TRPM7 in 293-M7shRNA2 cells
was reduced by approximately 80% compared to control cells
[10]. Interestingly, depletion of TRPM7 in the 293-M7shRNA2
cell line rendered the cells more resistant to cell stress induced by
several well known chemical apoptotic stimuli, including staur-
osporine, doxorubicin, and cycloheximide (Fig. 6B). Conversely,
overexpression of TRPM7 in 293-TRPM7 cells increased the
sensitivity of these cells to death by these same chemical agents
(Fig. 6C). Having shown that knockdown of TRPM7 in HEK-293
cells protects against cell death by several forms of apoptotic
stimuli, we next tested whether one of the TRPM7 channel
blockers would similarly increase resistance to cell stress. Long-
term treatment (48 hr) of HEK-293 cells with MK886 and NDGA
caused cell toxicity, thereby precluding their use in this
experiment. However, application of AA861 to 293-shRNA-C
cells reduced cell death caused by exposure to staurosporine,
doxorubicin, and cycloheximide to a level similar to that observed
for the TRPM7-knockdown cell line (Fig. 6D). These data reveal
the potential for TRPM7 channel blockers to be employed to
reduce cell death under pathological conditions.
Discussion
Stroke is the third leading cause of death in the United States as
well as a major cause of disability [37]. Considerable efforts have
been spent on developing treatments for stroke, but they have been
met with limited success [11]. For example, the contribution of
excitotoxicity mediated by glutamatergic NMDA receptors to
ischemia-induced cell death is well appreciated, however, blockers
of these receptors are not well tolerated and are only effective for a
very short time following the onset of ischemia [11]. Thus, the
identification of new targets for pharmacological intervention in
stroke is urgently needed.
Two studies by the same group have highlighted the importance of
TRPM7 to ischemic cell death. The earlier study demonstrated that
knockdown of TRPM7 dramatically reduced neuronal cell death
induced by oxygen glucose deprivation (OGD) using an in vitro model
of ischemia [11]. This work was subsequently followed by
experiments to demonstrate the protective effect of knockdown of
TRPM7 by RNA interference following ischemia using an in vivo
model [12]. More recently, a study by Inoue and coworkers revealed
that TRPM7 is involved in Zn
2+-induced injury of cultured mouse
cortical neurons [38]. Collectively, these studies strongly suggest that
TRPM7 may be an effective pharmacological target for stroke
treatment; however, compounds that could potentially be used
clinically against the channel have not been identified.
In this study we have identified the 5-LOX inhibitors NDGA,
AA861, and MK886 as potent blockers of TRPM7 channel
activity. The compounds were also effective at inhibiting TRPM7
channel function, as application of these molecules prevented
TRPM7-induced cell rounding as well as cell death caused by low
extracellular divalent cations or several forms of apoptotic stimuli.
NDGA, AA861, and MK886 were originally identified by their
capacity to inhibit 5-LOX [39,40,41], however, several lines of
evidence suggest that these compounds block TRPM7 channel
currents directly and independent of their inhibitory effects on 5-
LOX enzymatic activity. Transfection of the dsiRNA targeting 5-
LOX failed to lower TRPM7 whole cell currents compared to cells
transfected with the control dsiRNA, although transfection of
dsiRNAs targeting the 5-LOX partially interfered with TRPM7-
mediated cell rounding. It has been reported that 5-LOX is
involved in the regulation of cell adhesion, so the effects of the 5-
LOX dsiRNAs on TRPM7-induced cell rounding are likely due to
direct knockdown of 5-LOX expression [24]. In addition, we were
unable to reverse AA861’s blockade of TRPM7 channel activity
by perfusion of the 5-LOX product 5-HPETE or its downstream
metabolites into the extracellular bath solution. Likewise, inclusion
of either 5-HPETE, LTD4, and LTB4 into the internal pipette
solution did not prevent the inhibition of TRPM7 channel activity
by AA861. Finally, the other two 5-LOX inhibitors, 5,6-DAA and
Figure 2. The effects of 5-LOX inhibitors on TRPM7 channel
activity. Application of the 5-LOX inhibitors AA861 (A), MK886 (C), and
NDGA (E) to 293-TRPM7 expressing cells decreased the heterologously
expressed TRPM7 current amplitude over time (+100 mV). Representa-
tive traces showing the TRPM7 current-voltage relationship before and
after application of AA861 (B), MK886 (D), and NDGA (F). In contrast, the
5-LOX inhibitor, zileuton, did not alter the TRPM7 current amplitude
over time (G) or its current-voltage relationship (H). The above
experiments were performed a minimum of 10 times with similar
results.
doi:10.1371/journal.pone.0011161.g002
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tively, these results strongly indicate that NDGA, AA861, and
MK886 block TRPM7 channel currents independent of their
actions on 5-LOX enzymatic activity.
NDGA, AA861, and MK886 did not alter TRPM7 protein
expression or its concentration on the cell surface, leaving it unclear
how these compounds may be interfering with TRPM7 channel
activity. NDGA is a lipophilic reducing agent that blocks catalysis by
reducing the active site iron in 5-LOX, whereas AA861 competes
with binding of arachadonic acid to the enzyme [21,42]. The
structurally unrelated indole-containing MK886 is also lipophilic,
blocking 5-LOX activity by binding to FLAP, a membrane protein
that facilitates 5-lipoxygenase enzymatic activity by enhancing the
delivery of arachidonic acid to 5-LOX [43]. Thus, the compounds
may be blocking TRPM7 directly in the membrane or by interfering
with binding of lipid to the channel.
Since NDGA, AA861, and MK886 effectively block the
endogenous TRPM7 current, a reevaluation of the results of
experimental studies employing these compounds is warranted.
Administration of 5-LOX inhibitors has been shown to reduce
tissue damage in rodent models of cerebral ischemia and
myocardial ischemia-reperfusion injury [44,45,46,47]. However,
no significant difference in the infarct size between control and
5-LOX knockout mice was observed using either a heart or brain
model of ischemic injury [48,49]. As knockdown of the TRPM7
channel reduces the pathogenesis of brain ischemia, it is tempting
to speculate that 5-LOX inhibitors achieve a portion of their
cellular protective effects by blocking the TRPM7 channel.
Indeed, the 5-LOX inhibitors AA861 and NDGA were effective
in reversing TRPM7-induced cell death when cells are cultured in
low extracellular divalent cations. In addition, both knockdown of
TRPM7 and application of AA861 were effective in reducing cell
death caused by apoptotic stimuli. We conclude that NDGA,
AA861, and MK886 are effective blockers of TRPM7 channel
activity independent of their actions on 5-LOX. These compounds
will be valuable reagents for identifying and characterizing native
TRPM7 currents, as well as for blocking the physiological and
pathological functions of the channel in vivo.
Materials and Methods
Reagents
Indomethacin, a specific COX inhibitor, nordihydroguaiaretic acid
(NDGA), a lipoxygenase inhibitor, and staurosporine were from
Calbiochem/EMD Biosciences (San Di e g o ,C A ) .B a i c a l e i n ,as e l e c t i v e
inhibitor of 12-LOX, PD146176, a selective inhibitor of 15-LOX, two
Figure 3. The effect of 5-LOX on TRPM7-mediated cell rounding and TRPM7 current density. (A) A western blot using an antibody against
5-LOX revealed the efficiency of the dsiRNA-mediated knockdown of endogenous 5-LOX in 293-TRPM7 cells. 293-TRPM7 cells were transfected with
10 nM dsiRNAs targeting 5-LOX (dsiLOX5-1 & dsiLOX5-2) and the non-silencing control dsiRNA (dsiCT). Cells were lysed 48 hours after transfection. A
western blot of b-actin is shown to demonstrate the equal loading of samples. (B) Transfection of dsiRNAs targeting 5-LOX modestly decreased
TRPM7-mediated cell rounding. (C) Quantification of the degree of cell rounding under the conditions depicted in (B). Values are presented as the
mean 6 standard deviation of three independent experiments. The asterisk indicates a significant difference in cell rounding between 5-LOX
knockdown (dsiLOX5-1 & dsiLOX5-2) and control cells (dsiCT), using Student’s t test (p,0.05) (D) Knockdown of 5-LOX did not appreciably decrease
TRPM7’s current density at +100 mV in 293-TRPM7 expressing cells transfected with dsiLOX5-2 compared to cells transfected with the control (dsiCT).
p=0.2869 was compared with control cells (dsiCT) using Student’s t test (p.0.1).
doi:10.1371/journal.pone.0011161.g003
TRPM7 Channel Blockers
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diynyl)-3,5,6-trimethyl-1,4-benzoquinone (AA861) and 5,6-dehydro-
arachidonic acid (5,6-DAA), doxorubicin and cycloheximide were
from Sigma (St. Louis, MI). 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-
isopropylindol-2-yl]-2,2-dimethylpropanoic acid (MK886), a specific
inhibitor of FLAP, and two kinds of downstream metabolites from 5-
hydroperoxyeicosatetraenoic acid (5-HPETE), leukotriene B4 and
leukotriene D4, were from Cayman (Ann Arbor, MI). 5-HPETE, and
arachidonic acid, the product and substrate of 5-LOX respectively,
were from Biomol (Plymouth, PA). (RS)-N-[1-(1-benzothien-2-
yl)ethyl]-N-hydroxyurea (zileuton), the inhibitor of 5-LOX, was from
Tocris (Ellisville, MO). All other chemicals were from Sigma (St.
Louis, MI) unless otherwise indicated.
Cell Lines
A description and characterization of the 293-TRPM7 cell line
expressing hemagglutinin (HA) tagged murine TRPM7 (GenBank
Accession # AF376052), of the 293-M7shRNA2 cells expressing a
shRNA targeting human TRPM7 under tetracycline control, and
of the 293-shRNA-C cells expressing a non-silencing control
shRNA was previously described [10]. The Flp-In T-Rex 293 cell
line (HEK-TR) used to construct 293-M7shRNA2, 293-shRNA-
C, and 293-TRPM7 cell lines was from Invitrogen (Carlsbad, CA).
The overexpression of HA-tagged TRPM7 in 293-TRPM7 cells
was induced by the addition of tetracycline (1 mg/ml) to the
growth medium.
Cell Rounding Assay
Phase-contrast images of 293-TRPM7 cells were obtained with
a phase-contrast 10X UPlanFI objective using an Olympus IX70
microscope equipped with an environmental chamber at a
temperature of 37uC. Three random fields were selected in each
treatment, and every treatment was repeated in three independent
experiments. Changes in cell morphology were scored manually
employing the following criteria: Cells that had a fully-rounded
cell body with no membrane extension processes were given one
point. Partially-rounded cells with one or two membrane extension
processes were assigned half-a-point. Non-rounded cells having
three or four membrane extension processes and with a cell
morphology similar to wildtype HEK-293 cells, were given zero
points. The IC50 was determined by plotting the logarithm of
degree of cell rounding versus the logarithm of the concentration
of drug used and fitting to a modified version of the Hill equation.
A x
2 test was used to test differences in cell rounding.
Knockdown of 5-lipoxygenase in 293-TRPM7 Cells
The Dicer substrate RNA interferences (dsiRNAs) used to
knockdown 5-LOX were from Integrated DNA Technologies
Figure 4. The effect of 5-LOX inhibitors on TRPM7 protein
expression and cell surface concentration. (A) 293-TRPM7
expressing cells were treated with NDGA (10 mM), AA861 (10 mM),
and MK886 (10 mM) for 24 hours. Control HEK-293 cells not expressing
the channel (HEK-TR) as well as 293-TRPM7 cells, treated or not treated
with the 5-LOX inhibitors (UT), were subjected to surface labeling with
biotin. The cells were lysed and TRPM7 was subsequently immuno-
precipitated using a HA antibody and the amount of biotinylated
protein was detected by western blotting using Avidin-HRP to detect
the biotin label. Untreated cells (UT) that were not biotinylated (-)
served as a negative control. Western blotting using a monoclonal
antibody against the HA tag indicated that the 5-LOX inhibitors did
not appreciably affect TRPM7 expression. In addition, detection of the
biotin label indicated that 5-LOX inhibitors did not affect the surface
concentration of the channel. The HEK-TR cell line, from which 293-
TRPM7 cells were derived, was used as a negative control. (B)
Transfection of 293-TRPM7 cells with dsiRNAs against 5-LOX (dsiLOX5-
1 & dsiLOX5-2) did not affect TRPM7 surface levels or protein
expression compared to non-transfected (NT) cells or cells transfected
with the control (dsiCT).
doi:10.1371/journal.pone.0011161.g004
Figure 5. The effects of 5-LOX inhibitors on endogenous
TRPM7 channel activity. Application of the 5-LOX inhibitors AA861
(A), MK886 (C), and NDGA (E) decreased the endogenous TRPM7 current
amplitude in HEK-293 cells over time (+100 mV). Representative traces
showing the TRPM7 current-voltage relationship before and after
application of AA861 (B), MK886 (D), and NDGA (F). The above
experiments were performed a minimum of 5 times with similar results.
doi:10.1371/journal.pone.0011161.g005
TRPM7 Channel Blockers
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to create the dsiRNAs: dsiLOX5-1; 59GCA ACA CCG ACG
UAA AGA ACU GGA A-39 and 59-UUC CAG UUC UUU ACG
UCG GUG UUG CUU-39 and for dsiLOX5-2; 59-GGU AGA
CAU CUA CUA CGA GGG CGAC-39 and 59-GUC GCC CUC
GUA GUA GAU GUC UAC CAC-39. A nonsilencing sequence
tagged with Cy3 (59Cy3-TCC UUC CUC UCU UUC UCU
CCC UUG UGA-39 and 59Cy3-TCA CAA GGG AGA GAA
AGA GAG GAA GGA) was used to make dsiCT. 293-TRPM7
cells were transfected with 10 nM of dsiRNA (dsiCT or dsiLOX5)
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). To detect
5-LOX, cells were lysed in ice-cold radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris (pH 7.4), 150 mM NaCl,
1 mM ethylenediaminetetraacetic acid, 1% IGEPAL CA-630,
0.5% (w/v) deoxycholate, 0.1% (w/v) SDS, and 10 mM
iodoacetamide) containing protease inhibitors (Roche Applied
Science, Indianapolis, IN). 5-LOX was resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and western blotting using the polyclonal antibody (N-19) against
5-LOX (Santa Cruz Biotechnology, Santa Cruz, CA). The
SuperSignal West Dura Maximum Sensitive Substrate (Pierce,
Rockford, IL) was used for immunochemiluminescence detection.
Detection of Total and Cell Surface TRPM7 Protein
Expression
293-TRPM7 cells were washed three times with ice-cold PBS.
Intact cells were incubated with 1 mg/ml sulfo-NHS-LC-biotin
(Pierce, Rockford, IL) for 30 min at 4uC. Unreacted biotin was
Figure 6. The effects of 5-LOX inhibitors on cell viability. (A) Overexpression of TRPM7 in HEK-293 cells cultured in low extracellular
divalent cations (0.5 mM Ca
2+ and 0 mM Mg
2+) increased cell death compared to expressing cells grown in HBSS containing 1.8 mM Ca
2+ and
1m MM g
2+. Application of AA861 (10 mM) and NDGA (10 mM) but not zileuton (10 mM) increased the cell viability of TRPM7-expressing cells in
response to reduced extracellular divalent cations. Cell viability was measured after 48 hours treatment by manual cell counting and trypan blue
staining. (B) Knockdown of TRPM7 in HEK-293 cells rendered the cells more resistant to cell stress. Cell viability of TRPM7-knockdown 293-
M7shRNA2 and the control 293-shRNA-C cell line in response to 48 hours treatment with the apoptotic stimulating agents doxorubicin (DOX) at
0.25 mM, cycloheximide (CHX) at 1 mg/ml, and staurosporine (STS) at 0.25 mM. Cell viability was measured using the MTT assay. (C)
Overexpression of TRPM7 in 293-TRPM7 cells increased their sensitivity to cell death by DOX, STS, and CHX. 293-TRPM7 cells were treated with
0.0625 mMD O X ,1mg/ml CHX, and 0.25 mM STS for 48 hours with or without pre-treatment with TET for 18 hours to induce protein expression.
Cell viability was determined using the MTT assay. (D) Application of the 5-LOX inhibitor AA861 (10 mM), but not zileuton (10 mM), to 293-shRNA-
C cells increased their resistance to cell death by DOX (0.25 mM), CHX (1 mg/ml) and STS (0.25 mM) to a level similar to 293-M7shRNA2 cells not
treated with AA861. Cell viability was determined by manual cell counting and trypan blue staining. All data are presented as the mean 6
standard deviation of three independent experiments. The asterisk indicates a significant difference in cell viability between two different
treatments using Student’s t test (p,0.05).
doi:10.1371/journal.pone.0011161.g006
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l y s e di ni c e - c o l dR I P Ab u f f e rc o n taining protease inhibitors.
Cell lysates were incubated with anti-HA affinity matrix (Sigma)
at 4uC overnight. The immunoprecipitates were washed
extensively and analyzed by SDS-PAGE and western blotting
with avidin-horseradish peroxidase (Bio-Rad, Hercules, CA) for
detecting surface expression of TRPM7 and a monoclonal HA
antibody (Roche Applied Science) for detecting TRPM7. The
SuperSignal West Dura Maximum Sensitive Substrate (Pierce,
Rockford, IL) was used for immunochemiluminescence detec-
tion.
Electrophysiological Recordings
The voltage-clamp technique used to evaluate the whole-cell
currents of TRPM7 expressed in HEK-293 cells was previously
described [10]. Briefly, whole-cell current recordings of TRPM7-
expressing cells were elicited by voltage stimuli lasting 250 ms
delivered every 1 second using voltage ramps from 2120 to
+100 mV. Data was digitized at 2 or 5 kHz and digitally filtered
off-line at 1 kHz. The internal pipette solution for macroscopic
current recordings contained (in mM) 145 Cs-methanesulfonate, 8
NaCl, 10 EGTA, and 10 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES), pH adjusted to 7.2 with CsOH. The free
Mg
2+ concentration in the pipette was ,1 nM. The extracellular
solution for whole-cell recordings contained (in mM) 140 NaCl, 5
KCl, 2 CaCl2, 20 HEPES, and 10 glucose, pH adjusted to 7.4 with
NaOH. Extracellular solution was perfused through a fast-
perfusion system which can exchange external solutions within
3 s. Unless otherwise stated, each compound was included in the
external solution and applied to the cells after TRPM7 current
reached steady state. Compounds were washed out once the
maximal effect was observed.
Cell Viability Measurements
The assay of the effects of low extracellular divalent cations on
the cell viability of 293-TRM7 expressing cells was performed as
described with the following modifications [36]. Briefly, 293-
TRPM7 cells were cultured on poly-L-lysine coated plates in
Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal
bovine serum (FBS). After 20 hr with or without tetracycline
induction, cells were washed twice with Hanks’ balanced salt
solution (HBSS) (121 mM NaCl, 5 mM KCl, 20 mM D-glucose,
20 mM Hepes, and 1 mM Na-pyruvate). Cells were incubated in
HBSS with normal divalent cations (1 mM MgCl2, 1.8 mM
CaCl2) or with reduced extracellular divalent cations (0 mM
MgCl2, 0.5 mM CaCl2) and treated with 10 mM of the following
inhibitors, Zileuton, AA861 and NDGA, at 37uC for 48 hr. Cells
were then trypsinized and cell viability was determined using the
trypan blue exclusion assay.
To assess the resistance of cells to apoptotic stimuli cells were
treated with doxorubicin (DOX), staurosporine (STS), or cyclo-
heximide (CHX) for 48 hrs to induce cell death. Viability was
determined by MTT assay or manual cell counting by trypan blue
exclusion assay. For the MTT assay, cells were incubated with
0.1 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) for 4 hours and then dissolved in 100 ml dimethyl
sulfoxide. The absorbance at 570 nm was measured and
normalized to untreated cells.
Supporting Information
Figure S1 The effects of higher concentrations of 5-LOX
inhibitors on TRPM7 channel activity. Application of the 5-LOX
inhibitors AA861 (A) and NDGA (C) to 293-TRPM7 expressing
cells decreased TRPM7 current amplitude over time (+100 mV).
Representative traces showing the TRPM7 current-voltage
relationship before and after application of AA861 (B) and NDGA
(D). The above experiments were performed a minimum of 3 to 5
times with similar results.
Found at: doi:10.1371/journal.pone.0011161.s001 (0.32 MB TIF)
Figure S2 Characterization of the 5-LOX dsiRNAs. (A) A
western blot demonstrating that cotransfection of cDNA
encoding GFP-5-LOX with dsiRNA targeting 5-LOX (dsi-
LOX5-1 & dsiLOX5-2) reduced expression of GFP-5-LOX
compared to cells transfected with GFP-5-LOX alone (-) or with
GFP-5-LOX and the control dsiRNA (dsiCT). A western blot of
b-actin is shown to demonstrate equal loading of the samples. (B)
Western blot showing that cotransfection of dsiLOX5-1 and
dsiLOX5-2 with GFP-15-LOX-2 did not reduce expression of
GFP-15-LOX-2 compared to cells transfected with GFP-15-
LOX-2 alone or with GFP-15-LOX-2 and the control dsiRNA
(dsiCT). A western blot of b-actin is shown to demonstrate equal
loading of the samples.
Found at: doi:10.1371/journal.pone.0011161.s002 (0.24 MB TIF)
Figure S3 The 5-LOX product 5-HPETE and its metabolites
LTB4 and LTD4 do not reverse inhibition of TRPM7 current by
AA861. Application of the 5-LOX inhibitor AA861 to 293-
TRPM7 expressing cells dramatically reduced TRPM7 current
amplitudes (+100 mV). Coadministration of the 5-LOX product
5-HPETE (A) as well as its metabolites LTB4 (C) and LTD4 (E)
to the external solution did not restore TRPM7 current
amplitudes over time. Similarly, inclusion of 5-HPETE (B),
LTB4 (D), and LTD4 (F) in the internal pipette solution did not
prevent inhibition of TRPM7 channel activity by AA861. The
above experiments were performed a minimum of 10 times with
similar results.
Found at: doi:10.1371/journal.pone.0011161.s003 (0.27 MB TIF)
Figure S4 Effects of the 5-LOX inhibitor 5,6-DAA and
arachidonic acid on TRPM7 channel activity. (A) Application of
the 5-LOX inhibitor 5,6-DAA (5 mM) to 293-TRPM7 expressing
cells had no effect on TRPM7 current amplitudes (+100 mV,
n=5). 1.5% ethanol (EtOH) was employed as a vehicle control
and caused a very small decrease in the current amplitude. (B)
Representative traces showing the TRPM7 current-voltage
relationship before and after application of 5,6-DAA and 1.5%
ethanol (EtOH). (C) Application of arachidonic acid (10 mM) to
293-TRPM7 expressing cells had no effect on TRPM7 current
amplitudes (+100 mV, n=6). (D) Representative traces showing
the TRPM7 current-voltage relationship before and after
application of arachidonic acid.
Found at: doi:10.1371/journal.pone.0011161.s004 (0.39 MB TIF)
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